Olubusayo Obayan
Dermatology · Austin, TXNPI 1740573997
Payments from drug & device makers
Across 58 payments — averaging $32.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$298
- Sanofi$289
- EPI Health, LLC$235
- Janssen Scientific Affairs, LLC$150
- AbbVie$121
- Incyte Corporation$99
- plus $678 from 15 others
What the payments were for
- Food & beverage$1,85799%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 4 | $298 |
| Sanofi | 7 | $289 |
| EPI Health, LLC | 2 | $235 |
| Janssen Scientific Affairs, LLC | 1 | $150 |
| AbbVie | 7 | $121 |
| Incyte Corporation | 5 | $99 |
| Novartis | 5 | $96 |
| Merz North America, Inc. | 1 | $80 |
| Regeneron Healthcare Solutions, Inc. | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Mayne Pharma Commercial LLC | 3 | $57 |
| Medimetriks Pharmaceuticals, Inc. | 3 | $50 |
| LEO Pharma Inc. | 2 | $50 |
| VYNE Pharmaceuticals Inc. | 2 | $41 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| Amgen | 1 | $34 |
| Johnson & Johnson | 2 | $32 |
| Pfizer | 2 | $27 |
| Dermavant Sciences, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Arcutis Biotherapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sitavig$218
- Cloderm$218
- Minolira 105mg$218
- Minolira 135mg$218
- Rhofade$218
- Tremfya$150
- EPSOLAY$133
- ORACEA$133
- AKLIEF$133
- LIBTAYO$104
How this compares
$1,870 in reported general payments places this provider in the 30th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clindamycin-Benzoyl PeroxideClindamycin Phos/Benzoyl Perox | 12 | $523 |
| Fluocinonide | 11 | $307 |
| Ketoconazole | 14 | $273 |
| Minoxidil | 11 | $164 |
| Hydroxychloroquine Sulfate | 13 | $135 |
| Hydrocortisone | 16 | $92 |
| Triamcinolone Acetonide | 12 | $73 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Austin
- Edward LainAustin$12M
- Janet DuboisAustin$3.5M
- Daniel CarrascoAustin$1.4M
- Dale SchaeferAustin$1M
- Heidi PratherAustin$543K
- Ali ShahbazAustin$413K
- David BushoreAustin$385K
- Blakely RichardsonAustin$279K
- Stephen TyringWebster$14.1M
- Mark LeeSan Antonio$10.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.